Basic Stats
| CIK | 1742927 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Reviva Pharmaceuticals Holdings, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 Reviva Pha |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporatio |
|
| August 14, 2025 |
Exhibit 99.1 Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 |
|
| June 26, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 26, 2025, between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms a |
|
| June 26, 2025 |
Exhibit 4.2 SERIES D COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June , 2025 THIS SERIES D COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| June 26, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-276848 PROSPECTUS SUPPLEMENT (To Prospectus dated February 13, 2024) 20,000,000 Shares of Common Stock Series C Common Warrants to Purchase up to 20,000,000 Shares of Common Stock Series D Common Warrants to Purchase up to 20,000,000 Shares of Common Stock (and the Shares of Common Stock underlying such Series C Common Warrants and Series D Com |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation) |
|
| June 26, 2025 |
Exhibit 10.2 June 26, 2025 Reviva Pharmaceuticals Holdings, Inc. Attn: Laxminarayan Bhat, Chief Executive Officer 10080 N. Wolfe Rd., Suite SW3-200 Cupertino, CA 95014 Dear Dr. Bhat: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), that the Place |
|
| June 26, 2025 |
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering Exhibit 99.2 Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardi |
|
| June 26, 2025 |
Exhibit 4.1 SERIES C COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June , 2025 THIS SERIES C COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or aft |
|
| June 26, 2025 |
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering Exhibit 99.1 Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic dis |
|
| June 25, 2025 |
SUBJECT TO COMPLETION, DATED JUNE 25, 2025 Filed Pursuant to Rule 424(b)(5) Registration No. 333-276848 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any state or other jurisdiction where the |
|
| June 6, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction (Commission (IRS E |
|
| June 6, 2025 |
Letter of Moss Adams LLP to the Securities and Exchange Commission dated June 6, 2025. Exhibit 16.1 June 6, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Reviva Pharmaceuticals Holdings, Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therei |
|
| June 2, 2025 |
Investor Presentation Materials, dated June 2, 2025. Exhibit 99.2 |
|
| June 2, 2025 |
Exhibit 99.1 Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia – Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinflammatory marker |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction (Commission (IRS E |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction (Commission (IRS E |
|
| May 30, 2025 |
Up to $50,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-276848 PROSPECTUS SUPPLEMENT (to Prospectus dated February 13, 2024) Up to $50,000,000 Common Stock We have entered into a Sales Agreement, or the sales agreement, with B. Riley Securities, Inc. and A.G.P./Alliance Global Partners (each an “Agent”, and collectively, the “Agents”) relating to our shares of common stock, par value $0.0001 per sha |
|
| May 30, 2025 |
Exhibit 1.1 REVIVA PHARMACEUTICALS HOLDINGS, INC. Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement May 30, 2025 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Alliance Global Partners 590 Madison Ave, 28th Floor New York NY 10022 Ladies and Gentlemen: Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), confirms its a |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 15, 2025 |
Exhibit 99.1 Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights – 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, efficacy, adherence, and biomarker data expected in Q2 2025 – – Reg |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation) |
|
| April 3, 2025 |
As filed with the Securities and Exchange Commission on April 3, 2025 As filed with the Securities and Exchange Commission on April 3, 2025 Registration No. |
|
| April 3, 2025 |
Exhibit 19.1 STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES REVIVA PHARMACEUTICALS HOLDINGS, INC. STATEMENT OF COMPANY POLICY ON INSIDER TRADING AND POLICY REGARDING SPECIAL TRADING PROCEDURES Two copies of this Statement of Company Policy on Insider Trading and Policy Regarding Special Trading Procedures (collectively, this “Policy”) are being provi |
|
| April 3, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of filing this Annual Report on Form 10-K, Reviva Pharmaceuticals Holdings, Inc. (“us,” “our,” “we” or the “Company”), has two class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) our common stock, par valu |
|
| April 3, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Reviva Pharmaceuticals Holdings, Inc. |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 Reviva Pharmac |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38634 CUSIP NUMBER NOTIFICATION OF LATE FILING 76152G100 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation |
|
| March 31, 2025 |
Exhibit 99.1 Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights – Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 –– Cupertino |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction (Commission ( |
|
| December 23, 2024 |
Exhibit I LIMITED POWER OF ATTORNEY THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. |
|
| December 23, 2024 |
EXHIBIT II JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Reviva Pharmaceuticals Holdings, Inc. |
|
| December 18, 2024 |
Reviva Announces Proposed Public Offering Exhibit 99.1 Reviva Announces Proposed Public Offering CUPERTINO, Calif., December 16, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it is proposing |
|
| December 18, 2024 |
Exhibit 1.1 12,000,000 SHARES OF COMMON STOCK AND 24,000,000 WARRANTS OF REVIVA PHARMACEUTICALS HOLDINGS, INC. UNDERWRITING AGREEMENT December 16, 2024 Citizens JMP Securities, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Citizens JMP Securities, LLC 450 Park Avenue, 5th Floor New York, NY 10022 Ladies and Gentlemen: The undersigned, Reviva Pharmace |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporat |
|
| December 18, 2024 |
Exhibit 4.2 SERIES B COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: December 18, 2024 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| December 18, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262348 PROSPECTUS SUPPLEMENT (To Prospectus dated February 2, 2022) 12,000,000 Shares of Common Stock Series A Common Warrants to Purchase up to 6,000,000 Shares of Common Stock Series B Common Warrants to Purchase up to 12,000,000 Shares of Common Stock (and the shares of Common Stock underlying such Series A Common Warrants and Series B Commo |
|
| December 18, 2024 |
Exhibit 4.1 SERIES A COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: December 18, 2024 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| December 18, 2024 |
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants Exhibit 99.2 Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants CUPERTINO, Calif., December 16, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic di |
|
| December 16, 2024 |
SUBJECT TO COMPLETION, DATED DECEMBER 16, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-262348 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any state or other jurisdiction where the |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporat |
|
| December 16, 2024 |
Exhibit 99.1 Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia – Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full dat |
|
| December 12, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF REVIVA PHARMACEUTICALS HOLDINGS, INC. A Delaware Corporation Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Reviva Pharmaceuticals Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as f |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT -12-31 Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of inc |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 Reviv |
|
| November 14, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporat |
|
| November 14, 2024 |
RVPH / Reviva Pharmaceuticals Holdings, Inc. / Schonfeld Strategic Advisors LLC Passive Investment SC 13G 1 e664026sc13g-rph.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities |
|
| November 14, 2024 |
RVPH / Reviva Pharmaceuticals Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-rvph093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* REVIVA PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76152G100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this |
|
| November 14, 2024 |
Exhibit 99.1 Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights – 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in De |
|
| November 12, 2024 |
Exhibit 99.1 Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia – 108 patients have completed 1-year of treatment – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – Cupertino, Calif., November 12, 2 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporat |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction (Commission |
|
| August 23, 2024 |
RVPH / Reviva Pharmaceuticals Holdings, Inc. / SAXENA PARAG - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76152G 100 (CUSIP Number) Parag Saxena Vedanta Management, L.P. 250 West 55th Street, Ste 13D New York, NY 10019 (212) 710-5220 (Name, |
|
| August 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76152G100 (CUSIP Number) Attn: Laxminarayan Bhat, Chief Executive Officer 10080 N. Wolfe Rd., Suite SW3-200 Cupertino, CA 9501 |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdic |
|
| August 22, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-262348 PROSPECTUS SUPPLEMENT (To Prospectus dated February 2, 2022) 3,276,262 Shares of Common Stock Common Warrants to Purchase up to 4,761,905 Shares of Common Stock Pre-Funded Warrants to Purchase up to 1,485,643 Shares of Common Stock Underwriter Warrants to Purchase up to 238,095 Shares of Common Stock (and the shares of Common Stock under |
|
| August 21, 2024 |
Exhibit 99.1 Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the Market Under Nasdaq Rules CUPERTINO, Calif., August 21, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), infla |
|
| August 21, 2024 |
Exhibit 4.4 August 20, 2024 Holder of Warrants to Purchase Common Stock set forth on Exhibit A attached hereto Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the underwritten offering on or about the date hereof (the “Offering”) by Reviva Pharmaceuticals Holdings, Inc. (the “Company”) of its common stock, par value $0.0001 per share (“Common Stock”), and/or other secur |
|
| August 21, 2024 |
Exhibit 4.3 REPRESENTATIVE’S PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: 1 Initial Exercise Date: , 2024 Issue Date: , 2024 This REPRESENTATIVE’S PURCHASE WARRANT (the “Warrant”) certifies that, for value received, American Capital Partners, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereina |
|
| August 21, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: August , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date here |
|
| August 21, 2024 |
Exhibit 1.1 REVIVA PHARMACEUTICALS HOLDINGS, INC. 3,276,262 OF SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 1,485,643 SHARES OF SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE WARRANTS TO PURCHASE 4,761,905 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE Underwriting Agreement August 20, 2024 Titan Partners Group LLC, a division of American Capital Pa |
|
| August 21, 2024 |
Exhibit 4.2 PREFUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant No. Warrant Shares: Initial Exercise Date: , 2024 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction (Commission (IR |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 76152G100 (CUSIP Number) AUGUST 6, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule p |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 Reviva Pha |
|
| August 14, 2024 |
Exhibit 99.1 Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 – – Registrational RECOVER-2 trial in schizophrenia expected to initiate Q3 2024; topline data expected Q4 2025 – – European patent granted covering brilaroxazine use for treating pulmonary hypertension (PH) and pulmonary arte |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporatio |
|
| August 7, 2024 |
August 7, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tara Harkins Kevin Kuhar Re: Reviva Pharmaceuticals Holdings, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-38634 Dear Ms. Harkins and Mr. Kuhar: Reviva Pharmaceuticals Holdings, Inc. (the “Company,” “we, |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation) |
|
| July 9, 2024 |
Exhibit 99.1 Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension - Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary disease (COPD) or sickle cell disease (SCD) -Similar patents have also b |
|
| May 31, 2024 |
RVPH / Reviva Pharmaceuticals Holdings, Inc. / VEDANTA PARTNERS, LLC Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76152G 100 (CUSIP Number) Parag Saxena Vedanta Management, L.P. 250 West 55th Street, Ste 13D New York, NY 10 |
|
| May 29, 2024 |
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Cupertino, Calif., May 28, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic |
|
| May 29, 2024 |
PROSPECTUS SUPPLEMENT (To Prospectus dated February 2, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| May 29, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 28, 2024, between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| May 29, 2024 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: May , 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 29, 2024 |
Exhibit 4.2 May 28, 2024 Holder of Warrants to Purchase Common Stock set forth on Exhibit A attached hereto Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the registered direct offering on or about the date hereof (the “Offering”) by Reviva Pharmaceuticals Holdings, Inc. (the “Company”) of its common stock, par value $0.001 per share (“Common Stock”), and/or other secu |
|
| May 17, 2024 |
As filed with the Securities and Exchange Commission on May 17, 2024 As filed with the Securities and Exchange Commission on May 17, 2024 Registration No. |
|
| May 17, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Reviva Pharmaceuticals Holdings, Inc. |
|
| May 15, 2024 |
Exhibit 99.1 Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia – 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial expected in Q4 2024 |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation) |
|
| May 14, 2024 |
Exhibit 99.1 Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights – Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia – – Registrational RECOVER-2 trial expected to initiate Q2 2024; topline data expected Q3 2025 – – Topline data from 1-year open-label extension (OL |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 Reviva Ph |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation) |
|
| April 15, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation |
|
| April 15, 2024 |
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia Exhibit 99.1 Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia - FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia – - Topline data from 1-year open-label extension (OLE) long-ter |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| April 15, 2024 |
Exhibit 99.1 Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights – RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER-2 trial expected in the second quarter of 2024; topline data expected Q2 2025 – – Topline |
|
| April 15, 2024 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of filing this Annual Report on Form 10-K, Reviva Pharmaceuticals Holdings, Inc. (“us,” “our,” “we” or the “Company”), has two class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) our common stock, par valu |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation |
|
| April 15, 2024 |
Reviva Pharmaceuticals Holdings, Inc. Compensation Recovery Policy. Exhibit 97.1 REVIVA PHARMACEUTICALS HOLDINGS, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on November 13, 2023) 1. Purpose Reviva Pharmaceuticals Holdings, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Com |
|
| April 15, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-38634 CUSIP NUMBER NOTIFICATION OF LATE FILING 76152G100 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76152G100 (CUSIP Number) Steven M. Skolnick, Esq. Lowenstein Sandler LLP One Lowenstein Drive Roseland, NJ 07068 (973) 597-250 |
|
| February 14, 2024 |
RVPH / Reviva Pharmaceuticals Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-276848 PROSPECTUS Reviva Pharmaceuticals Holdings, Inc. $200,000,000 Common Stock Preferred Stock Warrants Debt Securities Subscription Rights Units We may offer, issue and sell from time to time together or separately, in one or more offerings, any combination of (i) our common stock, (ii) our preferred stock, which we may issue in one or more |
|
| February 9, 2024 |
Reviva Pharmaceuticals Holdings, Inc. Reviva Pharmaceuticals Holdings, Inc. February 9, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice Re: Reviva Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed on February 2, 2024 File No. 333-276848 Acceleration Request Requested Date: February 13, 2024 Requeste |
|
| February 2, 2024 |
Form of Senior Note (included in Exhibit 4.5).* Exhibit 4.5 REVIVA PHARMACEUTICALS HOLDINGS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between REVIVA PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicabl |
|
| February 2, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Reviva Pharmaceuticals Holdings, Inc. |
|
| February 2, 2024 |
As filed with the Securities and Exchange Commission on February 2, 2024 As filed with the Securities and Exchange Commission on February 2, 2024 Registration No. |
|
| February 2, 2024 |
Form of Subordinated Note (included in Exhibit 4.6).* Exhibit 4.6 REVIVA PHARMACEUTICALS HOLDINGS, INC., as Issuer and ●, as Trustee INDENTURE Dated as of ● Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between REVIVA PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapp |
|
| November 30, 2023 |
RVPH / Reviva Pharmaceuticals Holdings Inc. / VEDANTA PARTNERS, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76152G 100 (CUSIP Number) Parag Saxena Vedanta Management, L.P. 250 West 55th Street, Ste 13D New York, NY 10019 (212) 710-5220 (Name, |
|
| November 17, 2023 |
Exhibit 4.2 COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: November , 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| November 17, 2023 |
PROSPECTUS SUPPLEMENT (To Prospectus dated February 2, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| November 17, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 15, 2023, between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter |
|
| November 17, 2023 |
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Cupertino, Calif., November 16, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiomet |
|
| November 17, 2023 |
Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ———————————————————— FORM 10-Q ———————————————————— (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| November 14, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporat |
|
| November 14, 2023 |
Exhibit 99.1 Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights - RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia – - Consistent Phase 3 RECOVER and Phase 2 REFRESH f |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporat |
|
| November 14, 2023 |
Letter of Armanino LLP to the Securities and Exchange Commission dated November 14, 2023. Exhibit 16.1 November 14, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of the Current Report on Form 8-K/A of Reviva Pharmaceuticals Holdings, Inc. dated November 14, 2023, which we understand will be filed with the Securities and Exchange Commission, and we agree with the statements concerning our firm contained in such Fo |
|
| November 14, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdic |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporati |
|
| October 30, 2023 |
Exhibit 99.1 Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia - Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and cl |
|
| October 30, 2023 |
Investor Slide Deck, dated October 30, 2023. Exhibit 99.2 |
|
| October 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| October 4, 2023 |
Exhibit 16.1 October 4, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of the Current Report on Form 8-K of Reviva Pharmaceuticals Holdings, Inc. dated October 4, 2023, which we understand will be filed with the Securities and Exchange Commission, and we agree with the statements concerning our firm contained in such Form 8-K |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporatio |
|
| August 17, 2023 |
Exhibit 99.1 PRESS RELEASE Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia - 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - Cupertino, Calif., August 17 |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporatio |
|
| August 14, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporatio |
|
| August 14, 2023 |
Exhibit 99.1 Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights - Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 - Cupertino, Calif., August 14, 2023 – Reviva Pharmaceuticals Holdings, |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviva Pha |
|
| July 24, 2023 |
Letter of Armanino LLP to the Securities and Exchange Commission dated July 24, 2023 Exhibit 16.1 July 24, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of the Current Report on Form 8-K of Reviva Pharmaceuticals Holdings, Inc. dated July 24, 2023, which we understand will be filed with the Securities and Exchange Commission, and we agree with the statements concerning our firm contained in such Form 8-K. We |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) (Co |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) (Co |
|
| June 23, 2023 |
Exhibit 99.1 Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia - Enrollment ongoing at multiple sites in the US, Europe, and Asia – - Multifaceted activity of serotonin-dopamine stabilizer brilaroxazine supports potential for improvement in schizophrenia symptoms as well as accompanying neuroinflammation – - T |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 Reviva Pharm |
|
| May 15, 2023 |
Exhibit 99.1 Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights - Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023 – - Brilaroxazine topical liposomal-gel formulation (brilaroxazine lipogel) demonstrated proof-of-concept efficacy in the imiquimod-induced psoriatic mouse model – - IND submission for brilaroxazine lip |
|
| May 15, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) (Com |
|
| May 5, 2023 |
RVPH / Reviva Pharmaceuticals Holdings Inc. / Bhat Laxminarayan - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76152G100 (CUSIP Number) Steven M. Skolnick, Esq. Lowenstein Sandler LLP One Lowenstein Drive Roseland, NJ 07068 (973) 597-250 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation |
|
| April 5, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-267762 PROSPECTUS REVIVA PHARMACEUTICALS HOLDINGS, INC. Up to 3,359,684 shares of Common Stock underlying the Common Warrants Up to 1,383,399 shares of Common Stock underlying the Pre-Funded Warrants This prospectus relates to the resale from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stoc |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38634 REVIVA PHARMAC |
|
| March 30, 2023 |
Exhibit 99.1 Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights - Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed majority of non-clinical and clinical prelaunch measures for brilaroxazine New Drug Application (NDA) submission – - Positive clinic |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
EX-4.1 2 ex487038.htm EXHIBIT 4.1 Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of filing this Annual Report on Form 10-K, Reviva Pharmaceuticals Holdings, Inc. (“us,” “our,” “we” or the “Company”), has two class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amend |
|
| March 30, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Reviva Pharmaceutical Holdings, Inc. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or other jurisdiction of incorporation |
|
| February 14, 2023 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporatio |
|
| January 4, 2023 |
Reviva Pharmaceuticals Announces Letter to Shareholders Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Announces Letter to Shareholders Cupertino, Calif., January 4, 2022 ? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (?Reviva? or the ?Company?), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseas |
|
| November 14, 2022 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights - Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial - - Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023 - - $23.2M Million in Cash as of September 30, 2022 - Cupertino, Calif., Novem |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporat |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviv |
|
| October 18, 2022 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-267762 PROSPECTUS REVIVA PHARMACEUTICALS HOLDINGS, INC. Up to 3,359,684 shares of Common Stock underlying the Common Warrants Up to 1,383,399 shares of Common Stock underlying the Pre-Funded Warrants This prospectus relates to the resale from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stoc |
|
| October 13, 2022 |
October 13, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N. |
|
| October 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| October 6, 2022 |
As filed with the U.S. Securities and Exchange Commission on October 6, 2022 As filed with the U.S. Securities and Exchange Commission on October 6, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 85-4306526 (State or other jurisdiction of incorporation |
|
| October 6, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Reviva Pharmaceuticals Holdings, Inc. |
|
| September 12, 2022 |
RVPH / Reviva Pharmaceuticals Holdings, Inc. / VEDANTA PARTNERS, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76152G 100 (CUSIP Number) Parag Saxena Vedanta Management, L.P. 250 West 55th Street, Ste 13D New York, NY 10019 (212) 710-5220 (Name, Address and Te |
|
| September 7, 2022 |
Reviva Pharmaceuticals Holdings, Inc. 1,976,285 Shares of Common Stock PROSPECTUS SUPPLEMENT (To Prospectus dated February 2, 2022) Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| September 7, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 7, 2022 |
Exhibit 10.3 September 6, 2022 Reviva Pharmaceuticals Holdings, Inc. 19925 Stevens Creek Boulevard, Suite 100 Cupertino, CA 95014 Attn: Dr. Laxminarayan Bhat Dear Dr. Bhat: This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners (the ?Placement Agent?) and Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the ?Company?), that the Placement Agent |
|
| September 7, 2022 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?), dated as of September 6, 2022, between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms |
|
| September 7, 2022 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 7, 2022 |
Exhibit 99.1 Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules CUPERTINO, Calif., September 6, 2022 (GLOBE NEWSWIRE) - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (?Reviva? or the ?Company?), a clinical-stage pharmaceutical company developing therapies that seek to address unmet |
|
| September 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| September 7, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?), dated as of September 6, 2022, between Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms |
|
| August 15, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporatio |
|
| August 15, 2022 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights - Enrollment on pace for ongoing pivotal Phase 3 RECOVER trial - - Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 ? - $19.4 Million in Cash as of June 30, 2022 - Cupertino, Calif., August 15, 2022 ? Reviva Pharmaceut |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviva Pha |
|
| July 28, 2022 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| July 27, 2022 |
Exhibit 99.1 Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline Enrollment remains on pace for Reviva?s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022 More than 20% of the approximately 400 patients planned for Phase 3 trial already enrolled Reviva anticipates initiating t |
|
| July 27, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| June 27, 2022 |
Skip to Main Content U.S. Securities and Exchange Commission SEC.gov Search Form Search SEC.gov Company Filings | More Search Options About What We Do Commissioners Securities Laws SEC Docket Reports and Publications Careers Contact Divisions Corporation Finance Enforcement Investment Management Economic and Risk Analysis Trading and Markets National Exam Program All Divisions and Offices Enforcem |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviva Ph |
|
| May 16, 2022 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights - Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie Citrome, MD & Larry Ereshefsky, PharmD - Topline data for pivotal Phase 3 trial evaluating brilaroxazine f |
|
| May 16, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| March 23, 2022 |
424B3 1 rvph20220323c424b3.htm FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-251802 PROSPECTUS Reviva Pharmaceuticals Holdings, Inc. Up to 2,396,070 Shares of Common Stock 6,881,313 Shares of Common Stock Issuable Upon Exercise of Warrants 15,183 Warrants to Purchase Common Stock This prospectus relates to the issuance by us of up to an aggregate of up to 6,881,313 shares of our |
|
| March 23, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333- 255323 PROSPECTUS Reviva Pharmaceuticals Holdings, Inc. 11,966,600 Shares of Common Stock Issuable Upon Exercise of Previously Issued Warrants This prospectus relates to the issuance by us of up to (i) 6,900,000 shares of our common stock, $0.0001 par value per share (the ?Common Stock?), that may be issued from time to time upon the exercise |
|
| March 18, 2022 |
As filed with the Securities and Exchange Commission on March 18, 2022 As filed with the Securities and Exchange Commission on March 18, 2022 Registration No. |
|
| March 18, 2022 |
As filed with the Securities and Exchange Commission on March 18, 2022 POS AM 1 rvph20220317posam.htm As filed with the Securities and Exchange Commission on March 18, 2022 Registration No. 333-251802 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its cha |
|
| March 15, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation |
|
| March 15, 2022 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights - Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of December 31, 2021 - Cupertino, Calif., March 15, 2022 ? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38634 REVIVA PHARMACEUTICALS HOLDING |
|
| February 2, 2022 |
Reviva Pharmaceutical Holdings, Inc. Up to $12,900,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-262348 PROSPECTUS SUPPLEMENT (To Prospectus dated February 2, 2022) Reviva Pharmaceutical Holdings, Inc. Up to $12,900,000 Common Stock We have entered into an At The Market Offering Agreement, or the sales agreement, with H.C. Wainwright & Co., LLC, or Wainwright, dated January 26, 2022, relating to the sale of shares of our common stock, par |
|
| February 2, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262348 PROSPECTUS Reviva Pharmaceuticals Holdings, Inc. $150,000,000 Common Stock Preferred Stock Warrants Debt Securities Subscription Rights Units We may offer, issue and sell from time to time together or separately, in one or more offerings, any combination of (i) our common stock, (ii) our preferred stock, which we may issue in one or more |
|
| February 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporati |
|
| February 1, 2022 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia - RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - Cupertin |
|
| January 31, 2022 |
Reviva Pharmaceuticals Holdings, Inc. 19925 Stevens Creek Blvd., Suite 100 Cupertino, CA 95014 Reviva Pharmaceuticals Holdings, Inc. 19925 Stevens Creek Blvd., Suite 100 Cupertino, CA 95014 January 31, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Re: Reviva Pharmaceuticals Holdings, Inc. (the ?Company?) Registration Statement on Form S-3, as amended (File No. 333-262348) Accleration R |
|
| January 26, 2022 |
Form of Senior Note (included in Exhibit 4.5).** Exhibit 4.5 REVIVA PHARMACEUTICALS HOLDINGS, INC., as Issuer and ?, as Trustee INDENTURE Dated as of ? Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between REVIVA PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicabl |
|
| January 26, 2022 |
Form of Subordinated Note (included in Exhibit 4.6).** Exhibit 4.6 REVIVA PHARMACEUTICALS HOLDINGS, INC., as Issuer and ?, as Trustee INDENTURE Dated as of ? Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between REVIVA PHARMACEUTICALS HOLDINGS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapp |
|
| January 26, 2022 |
As filed with the Securities and Exchange Commission on January 26, 2022 As filed with the Securities and Exchange Commission on January 26, 2022 Registration No. |
|
| January 26, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporati |
|
| January 26, 2022 |
EX-1.2 2 ex328251.htm EXHIBIT 1.2 Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT January 26, 2022 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Reviva Pharmaceuticals Holdings, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. De |
|
| December 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporati |
|
| November 15, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255323 Registration No. 333-256519 Prospectus Supplement No. 3 Dated November 15, 2021 (To Prospectus Dated May 26, 2021) 8,000,000 Units Each Unit Consisting of One Share of Common Stock or Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase 0.75 of a Share of Common Stock REVIVA PHARMACEUTICALS HOLDINGS, INC. |
|
| November 15, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-251802 Prospectus Supplement No. 4 Dated November 15, 2021 (To Prospectus Dated May 14, 2021) Up to 2,887,104 Shares of Common Stock 6,881,313 Shares of Common Stock Issuable Upon Exercise of Warrants 556,313 Warrants to Purchase Common Stock REVIVA PHARMACEUTICALS HOLDINGS, INC. This Prospectus Supplement No. 4 supplements the prospectus of Re |
|
| November 15, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporat |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviv |
|
| November 15, 2021 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights - Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end - - Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with schizophre |
|
| October 26, 2021 |
Table of Contents United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| September 21, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-251802 Prospectus Supplement No. 3 Dated September 21, 2021 (To Prospectus Dated May 14, 2021) Up to 2,887,104 Shares of Common Stock 6,881,313 Shares of Common Stock Issuable Upon Exercise of Warrants 556,313 Warrants to Purchase Common Stock REVIVA PHARMACEUTICALS HOLDINGS, INC. This Prospectus Supplement No. 3 supplements the prospectus of R |
|
| September 21, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255323 Registration No. 333-256519 Prospectus Supplement No. 2 Dated September 21, 2021 (To Prospectus Dated May 26, 2021) 8,000,000 Units Each Unit Consisting of One Share of Common Stock or Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase 0.75 of a Share of Common Stock REVIVA PHARMACEUTICALS HOLDINGS, INC. |
|
| September 20, 2021 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorpora |
|
| August 16, 2021 |
424B3 1 rvph20210816424b3.htm FORM 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-251802 Prospectus Supplement No. 2 Dated August 16, 2021 (To Prospectus Dated May 14, 2021) Up to 2,887,104 Shares of Common Stock 6,881,313 Shares of Common Stock Issuable Upon Exercise of Warrants 556,313 Warrants to Purchase Common Stock REVIVA PHARMACEUTICALS HOLDINGS, INC. This Prospectus Supplement |
|
| August 16, 2021 |
Exhibit 4.3 REVIVA PHARMACEUTICALS HOLDINGS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of June 1, 2021 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of June 1, 2021 (?Agreement?), between Reviva Pharmaceuticals Holdings, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and Continental |
|
| August 16, 2021 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights -Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million - Expected to Initiate Pivotal Phase 3 Clinical Trial in Schizophrenia in Q4?21 -$35.8 Million in Cash as of June 30, 2021 Cupertino, Calif., Augus |
|
| August 16, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporatio |
|
| August 16, 2021 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June 1, 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereo |
|
| August 16, 2021 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: June 1, 2021 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on o |
|
| August 16, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255323 Registration No. 333-256519 Prospectus Supplement No. 1 Dated August 16, 2021 (To Prospectus Dated May 26, 2021) 8,000,000 Units Each Unit Consisting of One Share of Common Stock or Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase 0.75 of a Share of Common Stock REVIVA PHARMACEUTICALS HOLDINGS, INC. Th |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviva Pha |
|
| June 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| June 14, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 76152G 100 (CUSIP Number) Rahul Nayar 6700 Indian Creek Drive, Apt 1007 Miami Beach, FL 33141 (917) 710-5220 (Name, Address and Telephone Number of Pe |
|
| June 3, 2021 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 3, 2021 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Reviva Pharmaceuticals Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 76152G 100 (CUSIP Number) Parag Saxena Vedanta Management, L.P. 250 West 55th Street, Ste 13D New York, NY 10019 (212) 710-5220 (Name, Addre |
|
| June 3, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Reviva Pharmaceuticals Holdings, Inc. and further agree to the filing of this Joint Filing |
|
| June 3, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: June 3, 2021 VEDANTA ASSO |
|
| May 28, 2021 |
As filed with the Securities and Exchange Commission on May 28, 2021 As filed with the Securities and Exchange Commission on May 28, 2021 Registration No. |
|
| May 28, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-255323 Registration No. 333-256519 PROSPECTUS 8,000,000 Units Each Unit Consisting of One Share of Common Stock or Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase 0.75 of a Share of Common Stock We are offering 8,000,000 Units, with each Unit consisting of one share of our common stock, $0.0001 par value per |
|
| May 26, 2021 |
As filed with the Securities and Exchange Commission on May 26, 2021 As filed with the Securities and Exchange Commission on May 26, 2021 Registration No. |
|
| May 25, 2021 |
Exhibit 4.5 COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the |
|
| May 25, 2021 |
Form of Underwriting Agreement Exhibit 1.1 SHARES OF COMMON STOCK PRE- FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK, AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF REVIVA PHARMACEUTICALS HOLDINGS, INC. UNDERWRITING AGREEMENT , 2021 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Maxim Group LLC Investment Banking 405 Lexington Avenue, 2nd Floor New York, NY 101 |
|
| May 25, 2021 |
As filed with the Securities and Exchange Commission on May 25, 2021 Table of Contents As filed with the Securities and Exchange Commission on May 25, 2021 Registration No. |
|
| May 25, 2021 |
Exhibit 4.6 REVIVA PHARMACEUTICALS HOLDINGS, INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of , 2021 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of , 2021 (?Agreement?), between Reviva Pharmaceuticals Holdings, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and Continental Stock Transf |
|
| May 25, 2021 |
Exhibit 4.7 PRE-FUNDED COMMON STOCK PURCHASE WARRANT REVIVA PHARMACEUTICALS HOLDINGS, INC. Warrant Shares: Initial Exercise Date: , 2021 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| May 25, 2021 |
May 25, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N. |
|
| May 25, 2021 |
May 25, 2021 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: David Gessert Re: Reviva Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1, as amended (File No. 333-255323) Ladies and Gentlemen: As the underwriter of the proposed offering of Reviva Pharmaceuticals Holdings, Inc. (the ?Company?), we hereby join the Company?s request for accele |
|
| May 19, 2021 |
As filed with the Securities and Exchange Commission on May 19, 2021 Table of Contents As filed with the Securities and Exchange Commission on May 19, 2021 Registration No. |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38634 Reviva Ph |
|
| May 17, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-251802 PROSPECTUS REVIVA PHARMACEUTICALS HOLDINGS, INC. Up to 2,887,104 Shares of Common Stock 6,881,313 Shares of Common Stock Issuable Upon Exercise of Warrants 556,313 Warrants to Purchase Common Stock This prospectus relates to the issuance by us of up to an aggregate of up to 6,325,000 shares of our common stock, $0.0001 |
|
| May 17, 2021 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-251802 Prospectus Supplement No. 1 Dated May 17, 2021 (To Prospectus Dated May 14, 2021) Up to 2,887,104 Shares of Common Stock 6,881,313 Shares of Common Stock Issuable Upon Exercise of Warrants 556,313 Warrants to Purchase Common Stock REVIVA PHARMACEUTICALS HOLDINGS, INC. This Prospectus Supplement No. 1 supplements the prospectus of Reviva |
|
| May 12, 2021 |
As filed with the Securities and Exchange Commission on May 12, 2021 Table of Contents As filed with the Securities and Exchange Commission on May 12, 2021 Registration No. |
|
| May 10, 2021 |
Form of Underwriting Agreement Exhibit 1.1 SHARES OF COMMON STOCK REVIVA PHARMACEUTICALS HOLDINGS, INC. UNDERWRITING AGREEMENT , 2021 Maxim Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Maxim Group LLC Investment Banking 405 Lexington Avenue, 2nd Floor New York, NY 10174 Ladies and Gentlemen: The undersigned, Reviva Pharmaceuticals Holdings, Inc., a company incorporated unde |
|
| May 10, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on May 10, 2021 Registration No. |
|
| May 10, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation) ( |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38634 REVIVA PHARMACEUTICALS HOLDI |
|
| April 19, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on April 16, 2021 Registration No. |
|
| April 15, 2021 |
Exhibit 10.1 [***] Text omitted pursuant to Item 601(a)(6) of Regulation S-K April 14, 2021 Marc Cantillon, MD [***] Re: Employment Terms Dear Marc: This letter sets forth the terms and conditions of your continued employment as Chief Medical Officer of Reviva Pharmaceuticals Holdings, Inc. (the ?Company?), effective as of the date that you accept the terms herein by counter-signing this letter be |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation |
|
| March 29, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-251802 PROSPECTUS REVIVA PHARMACEUTICALS HOLDINGS, INC. Up to 2,887,104 Shares of Common Stock 6,881,313 Shares of Common Stock Issuable Upon Exercise of Warrants 556,313 Warrants to Purchase Common Stock This prospectus relates to the issuance by us of up to an aggregate of up to 6,325,000 shares of our common stock, $0.0001 |
|
| March 25, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on March 25, 2021 Registration No. |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38634 REVIVA PHARMACEUTICALS HOLDI |
|
| March 22, 2021 |
Exhibit 99.1 PRESS RELEASE Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update -Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market- -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved- Cupertino, Calif., March 22, 2021 ? Reviva Pharmaceuticals Holdings, Inc. |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38634 85-4306526 (State or Other Jurisdiction of Incorporation |
|
| March 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38634 REVIVA PHARMACEUTICALS HOLDINGS, INC. (Exact nam |
|
| March 22, 2021 |
As filed with the Securities and Exchange Commission on March 22, 2021 Registration No. |
|
| March 22, 2021 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 11, 2021 Reviva Pharmaceuticals Holdings, Inc. (?us,? ?our,? ?we? or the ?Company?), has two class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) our common stock, par value $0.0001 per share (the ?Common Stoc |
